Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
The institution will be spread over an area of more than 8 acres
Vision loss due to Glaucoma can be prevented if it is detected and treated early
These approvals mark significant progress for Venus Remedies in expanding its market presence
The validations confirm the completion of the applications and commence the scientific review process
Acquisition of exclusive commercialization rights for European markets
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Subscribe To Our Newsletter & Stay Updated
